Document is current
Any future updates will be listed below
-
Authors
Rogado, Jacobo https://orcid.org/0000-0002-9795-8762
Pozo, Fernando
Troule, Kevin
Pacheco, María
Adrados, Magdalena
Sánchez-Torres, José Miguel
Al-Shahrour, Fátima
Aspa, Javier
Alfranca, Arantzazu
Romero-Laorden, Nuria
Colomer, Ramon
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PIE15/00068, PI17/01865, PI20/01458, PI22/00549, AEI/10.13039/501100011033, PI21/01111)
Fundación Mutua Madrileña (AP176822021)
Fundación Científica Asociación Española Contra el Cáncer (ideas semilla AECC 2019)
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 9 December 2024
First Online: 21 December 2024
Declarations
:
: Jacobo Rogado reports personal fees from Roche, AstraZeneca, Merck, Ferrer, Persan Farma, Fresenius Kabi, Sanofi, MSD, Abott; travel expenses from MSD, BMS, Roche, and AstraZeneca; and advisory consultancies from Fresenius Kabi, Abott, AstraZeneca, Sanofi, MSD, MAIA Biotech. Nuria Romero reports advisory consultancies from Ipsen, Janssen, Clovis, and Astra Zeneca and research funding from Janssen, MSD, and Pfizer. Ramon Colomer reports research funding from Roche, Janssen, BMS, and MSD. All of the declared conflicts of interest are outside of the submitted work. All other authors have no conflict to declare.
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Hospital Universitario La Princesa on 22 December 2016 under the code 2918.
: Informed consent was obtained from all patients involved in the study.
